Pipeline

Advanced medicines that demonstrate both strong clinical performance and benefits to patients.

Pipeline
90
+
compounds, devices or indications in development individually or under collaboration or license agreement
investment
$7.8
b
R&D investment in 2023
Commitment
50
+
programs are in mid and late-stage development
Novel
80
%
of compounds in clinical development with a novel mechanism of action

Innovative medicines for the future

Since our beginnings, AbbVie has been at the top of the global pharmaceutical industry innovation rankings. In 2020, $5.8 billion was invested in research and development. Our therapeutic pipeline is promising: in the next few years, we will produce innovations in the areas of immunology, virology, neurology and oncology.

You can find an overview of our pipeline here:

AbbVie pipeline (abbvie.com)

Popular Pages
External Links

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

Copyright © 2024 AbbVie Inc. North Chicago, Illinois, U.S.A.